Find Docosanol manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

7 RELATED EXCIPIENT COMPANIES

14EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1-docosanol, Docosan-1-ol, Behenyl alcohol, 661-19-8, Behenic alcohol, N-docosanol
Molecular Formula
C22H46O
Molecular Weight
326.6  g/mol
InChI Key
NOPFSRXAKWQILS-UHFFFAOYSA-N
FDA UNII
9G1OE216XY

Docosanol
Docosanol is a saturated 22-carbon aliphatic alcohol with antiviral activity. Docosanol has a distinct mechanism of action and inhibits fusion between the plasma membrane and the herpes simplex virus envelope, thereby preventing viral entry into cells and subsequent viral activity and replication. Docosanol is used topically in the treatment of recurrent herpes simplex labialis episodes and relieves associated pain and may help heal sores faster.
1 2D Structure

Docosanol

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
docosan-1-ol
2.1.2 InChI
InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
2.1.3 InChI Key
NOPFSRXAKWQILS-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCCCCCCCCCCCCCCCCCCCCO
2.2 Other Identifiers
2.2.1 UNII
9G1OE216XY
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-docosanol

2. Abreva

3. Behenyl Alcohol

4. Ik.2

2.3.2 Depositor-Supplied Synonyms

1. 1-docosanol

2. Docosan-1-ol

3. Behenyl Alcohol

4. 661-19-8

5. Behenic Alcohol

6. N-docosanol

7. Abreva

8. Docosyl Alcohol

9. Tadenan

10. Lidavol

11. Stenol 1822

12. Lanette 22

13. Docosanol [usan]

14. Lidakol

15. Stenol 1822a

16. Nacol 22-97

17. Ik 2

18. 30303-65-2

19. Naa 422

20. Nsc 8407

21. Docosanol (abreua)

22. Docosanol (abreva)

23. Docosanol (usan)

24. Nsc-8407

25. 9g1oe216xy

26. Chebi:31000

27. Ncgc00159370-02

28. Docosanol (van)

29. Erazaban

30. Herepair

31. Ik.2

32. Healip

33. Cachalot Be-22

34. Abreva (tn)

35. Hsdb 5739

36. Loxiol Vpg 1451

37. Einecs 211-546-6

38. Brn 1770470

39. Unii-9g1oe216xy

40. Ai3-36489

41. Ccris 8943

42. N-docosan-1-ol

43. C22 Alcohol

44. Docosanol-(1)

45. Mfcd00002939

46. 1-docosanol, 98%

47. Docosanol [ii]

48. Docosanol [hsdb]

49. Docosanol [vandf]

50. Dsstox_cid_7286

51. N-docosanol [mi]

52. Docosanol [mart.]

53. Ec 211-546-6

54. Docosanol [who-dd]

55. Dsstox_rid_78387

56. Dsstox_gsid_27286

57. Schembl51925

58. 4-01-00-01906 (beilstein Handbook Reference)

59. Behenyl Alcohol [inci]

60. Docosanol [orange Book]

61. Chembl1200453

62. Dtxsid4027286

63. Nsc8407

64. Hms2093p22

65. Pharmakon1600-01505729

66. Hy-b0222

67. Zinc6920384

68. Tox21_111611

69. Lmfa05000008

70. Nsc759235

71. S1637

72. Akos015902887

73. Ccg-213539

74. Db00632

75. Nsc-759235

76. Behenyl Alcohol, Ai3-36489, Behenic Alcohol, 1-docosanol, Docosyl Alcohol, Ik-2, Tadenan

77. Ncgc00159370-03

78. Ncgc00159370-04

79. Ncgc00159370-05

80. 1-docosanol, Purum, >=97.0% (gc)

81. Ac-19852

82. Cas-661-19-8

83. Sbi-0206938.p001

84. A8416

85. Am20100601

86. D0964

87. Ft-0622609

88. D03884

89. D70615

90. Ab01563123_01

91. Ab01563123_02

92. Sr-05000001915

93. Q3033497

94. Sr-05000001915-1

95. A3d72d45-625e-49b5-b0fc-394010b3485d

2.4 Create Date
2004-09-16
3 Chemical and Physical Properties
Molecular Weight 326.6 g/mol
Molecular Formula C22H46O
XLogP310.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count1
Rotatable Bond Count20
Exact Mass326.354866087 g/mol
Monoisotopic Mass326.354866087 g/mol
Topological Polar Surface Area20.2 Ų
Heavy Atom Count23
Formal Charge0
Complexity190
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameAbreva
PubMed HealthDocosanol (On the skin)
Drug ClassesAntiviral
Active IngredientDocosanol
Dosage FormCream
RouteTopical
Strength10%
Market StatusOver the Counter
CompanyGlaxosmithkline

2 of 2  
Drug NameAbreva
PubMed HealthDocosanol (On the skin)
Drug ClassesAntiviral
Active IngredientDocosanol
Dosage FormCream
RouteTopical
Strength10%
Market StatusOver the Counter
CompanyGlaxosmithkline

4.2 Therapeutic Uses

Topical docosanol is indicated in the treatment of recurrent oral-facial herpes simplex (fever blisters or cold sores) in adults. /Included in US product labeling/

Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 1236


Docosanol ... has been approved by the US FDA as a 10% ever-the-counter cream for treatment of recurrent orolabial herpes. Docosanol inhibits the in vitro replication of many lipid enveloped viruses, including HSV /(herpes simplex virus)/, at millimolar concentrations. It dose not directly inactivate HSV but appears to block fusion between the cellular and viral envelope membranes and inhibit viral entry into the cell. Topical treatment beginning within 12 hr of prodromal symptoms or lesion onset reduces healing time by about 1 day and appears to be well tolerated. Treatment initiation at papular or later stages provides no benefit. /Docosanol/

Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1322


Therap cat: Antiviral (topical)

O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 598


4.3 Drug Warning

Adverse effects occurring in 2% or more of patients receiving docosanol include headache (incidence similar to placebo), application site reaction (e.g., burning, stinging) (incidence similar to placebo), and herpes simplex outside the treatment area (incidence similar to placebo).

McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 3397


Docosanol 10% cream is recommended only for use on cold sores/fever blisters.

McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 3397


FDA Pregnancy Risk Category: B /NO EVIDENCE OF RISK IN HUMANS. Adequate, well controlled studies in pregnant women have not shown increased risk of fetal abnormalities despite adverse findings in animals, or, in the absence of adequate human studies, animal studies show no fetal risk. The chance of fetal harm is remote but remains a possibility./

Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 1237


4.4 Drug Indication

For the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Docosanol is a saturated 22-carbon aliphatic alcohol which exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol speeds the healing of cold sores and fever blisters on the face or lips. It also relieves the accompanying symptoms, including tingling, pain, burning, and itching. Docosanol cannot, however, prevent cold sores or fever blisters from appearing.


5.2 MeSH Pharmacological Classification

Antiviral Agents

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)


5.3 ATC Code

D06BB11

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


D - Dermatologicals

D06 - Antibiotics and chemotherapeutics for dermatological use

D06B - Chemotherapeutics for topical use

D06BB - Antivirals

D06BB11 - Docosanol


5.4 Absorption, Distribution and Excretion

Absorption

Topical absorption has been shown to be minimal under conditions reflecting normal clinical use.


Absorption of docosanol has been shown to be minimal under conditions reflecting normal clinical use. Of 209 plasma samples taken from ten subjects 24 hours after a multi-day test, only one had a docosanol level above the quantitation limits (19 nanograms/mL).

Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 1236


Long chain alcohols were detected in developing rat brain at their highest level of 0.0109% of the total lipids at the age of 10 days and decreased to 0.0036% at the age of 40 days. They consited mainly of hexadecanol, octadecanol, octadecenol, eicosanol, docosanol, and tetracosanol.

Natarajan V, Schmid HH; Lipids 12 (1): 128-30 (1977)


A mixture of cis-9[1(-14)C] octadecenol and [1(-14)C] docosanol was injected into the brains of 19-day-old rats, and incorporation of radioactivity into brain lipids was determined after 3, 12, and 24 hr. Both alcohols were metabolized by the brain but at different rates; each was oxidized to the corresponding fatty acid, but oleic acid was more readily incorporated into polar lipids. Substantial amounts of radioactivity were incorporated into 18:1 alkyl and alk-1-enyl moieties of the ethanolamine phosphoglycerides and into 18:1 alkyl moieties of the choline phosphoglycerides. Even after the disappearance of the 18:1 alcohol from the substrate mixture (12 hr), the 22:0 alcohol was not used to any measurable extent for alkyl and alk-1-enylglycerol formation.

PMID:916829 Natarajan V, Schmid HH; Lipids 12 (10): 872-5 (1977)


5.5 Metabolism/Metabolites

The 22-carbon fatty alcohol, n-docosanol, exhibits in vitro antiviral activity against several lipid-enveloped viruses including herpes simplex viruses 1 and 2 by a mechanism that interferes with normal viral entry into target cells. We previously reported that mammalian cells incorporate significant quantities of radiolabeled n-docosanol. Herein, we report that cells extensively metabolize the internalized fatty alcohol. This is evidenced by incorporation of up to 60% of cell-associated radiolabel into phospholipids that copurify with phosphatidylcholine and phosphatidylethanolamine. Analysis by chemical (Vitride) reduction suggests that a significant portion of n-docosanol is oxidized to n-docosanoic acid and then incorporated as an acyl group on polar lipids. A measurable amount of radiolabel, however, is resistant to Vitride reduction, consistent with incorporation of n-docosanol into ether lipids. The rate and extent of metabolic conversion of n-docosanol vary with the cell type and surfactant used to suspend the compound. Furthermore, the anti-HSV activity of n-docosanol is quantitatively proportional to the amount of metabolism observed. These findings suggest that the anti-HSV activity of n-docosanol involves cellular uptake and metabolism of the drug.

PMID:8906594 Pope LE et al; J Lipid Res 37 (10): 2167-78 (1996)


A mixture of cis-9[1(-14)C] octadecenol and [1(-14)C] docosanol was injected into the brains of 19-day-old rats. Both alcohols were metabolized by the brain but at different rates; each was oxidized to the corresponding fatty acid. Substantial amounts of radioactivity were incorporated into 18:1 alkyl and alk-1-enyl moieties of the ethanolamine phosphoglycerides and into 18:1 alkyl moieties of the choline phosphoglycerides.

Natarajan V, Schmid HH; Lipids 12 (10): 872-5 (1977)


5.6 Mechanism of Action

Docosanol works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV.


n-Docosanol-treated cells resist infection by a variety of lipid-enveloped viruses including the herpesviruses. Previous studies of the mechanism of action demonstrated that n-docosanol inhibits an event prior to the expression of intermediate early gene products but subsequent to HSV attachment. The studies reported here indicate that n-docosanol inhibits fusion of the HSV envelope with the plasma membrane. Evidence suggests that antiviral activity requires a time-dependent metabolic conversion of the compound. Cellular resistance to infection declines after removal of the drug with a t1/2 of approximately 3 h. Reduced expression of viral genes in n-docosanol-treated cells was confirmed by a 70% reduction in expression of a reporter gene regulated by a constitutive promoter inserted into the viral genome. Inhibited release in treated cells of virion-associated regulatory proteins--an immediate post entry event--was indicated by a 75% reduction in the expression of beta-galactosidase in target cells carrying a stably transfected lacZ gene under control of an HSV immediate--early promoter. Finally, the fusion-dependent dequenching of a lipophilic fluorescent probe, octadecyl rhodamine B chloride, inserted into the HSV envelope was significantly inhibited in treated cells. Inhibition of fusion between the plasma membrane and the HSV envelope, and the subsequent lack of replicative events, may be the predominant mechanism for the anti-HSV activity of n-docosanol.

PMID:9864049 Pope LE et al; Antiviral Res 40 (1-2): 85-94 (1998)


Docosanol reduces viral replication and activity by effectively inhibiting the fusion between the plasma membrane and the herpes simplex virus envelope.

Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 1236


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2018-11-05

Pay. Date : 2018-09-26

DMF Number : 33064

Submission : 2018-09-07

Status : Active

Type : II

Biophore

02

Duphat
Not Confirmed

02

Duphat
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-10-16

Pay. Date : 2015-06-08

DMF Number : 29410

Submission : 2015-06-19

Status : Active

Type : II

blank

03

Duphat
Not Confirmed

03

Duphat
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2020-10-15

Pay. Date : 2020-09-03

DMF Number : 35164

Submission : 2020-09-04

Status : Active

Type : II

blank

04

Duphat
Not Confirmed

04

Duphat
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-02-12

Pay. Date : 2023-12-27

DMF Number : 38621

Submission : 2023-12-20

Status : Active

Type : II

blank

05

Duphat
Not Confirmed

05

Duphat
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-09-27

Pay. Date : 2019-08-19

DMF Number : 33229

Submission : 2018-10-17

Status : Active

Type : II

blank

06

Sasol Germany Gmbh

Germany

USDMF

arrow
Duphat
Not Confirmed

07

Duphat
Not Confirmed

07

Duphat
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-07-02

Pay. Date : 2019-03-07

DMF Number : 33165

Submission : 2019-03-18

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI offers customized CDMO Solutions for API development and manufacturing services.

Flag Israel
Digital Content Digital Content

Docosanol IH

Date of Issue : 2022-05-26

Valid Till : 2025-05-25

Written Confirmation Number : WC-0002A2

Address of the Firm : A-2, A-2/1, A-2/2, UPSIDC Industrial Area, Bijnor Road, Gajraula

TAPI Company Banner

02

Actavis Inc

Ireland
Duphat
Not Confirmed
arrow

Actavis Inc

Ireland
arrow
Duphat
Not Confirmed

Docosanol IH

Date of Issue : 2021-07-29

Valid Till : 2022-08-15

Written Confirmation Number : WC-0199A1

Address of the Firm : Plot No. N-15, MIDC, Additional Ambernath, Anand Nagar, Ambernath (E), Thane-421...

blank

03

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Docosanol IH

Date of Issue : 2020-08-17

Valid Till : 2023-06-22

Written Confirmation Number : WC-0404A2

Address of the Firm : Plot No.40/A Sy.13,15,16,51,52 &182 J.N Pharma City Thanam village Parawada mand...

blank

04

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Docosanol IH

Date of Issue : 2020-08-17

Valid Till : 2023-06-22

Written Confirmation Number : WC-0404

Address of the Firm : Plot No.40/A Sy.13,15,16,51,52 &182 J.N Pharma City Thanam village Parawada mand...

blank

05

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Docosanol IH

Date of Issue : 2020-09-09

Valid Till : 2023-06-28

Written Confirmation Number : WC-0407

Address of the Firm : Sy. No. 205, 222 to 226, IDA Bonthapally bonthapally Village Jinnaram mandal med...

blank

06

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Docosanol IH

Date of Issue : 2020-02-24

Valid Till : 2020-06-28

Written Confirmation Number : WC-0407A6

Address of the Firm : Sy. No. 205, 222 to 226, IDA Bonthapally bonthapally Village Jinnaram mandal med...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

Docosanol

About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...

Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-approved API manufacturing facilities, a dedicated intermediate facility, and a R&D laboratory housing 400 scientists, Biophore has positioned itself as a global leader among API companies. It consistently ranks among the top 10 US DMF filers and has obtained over 150 patents worldwide in process and polymorph areas. Biophore's facilities have an impressive track record of successful audits by regulatory bodies such as USFDA, EMEA, ANVISA, COFEPRIS, and WHO GMP.
Biophore

02

arrow
Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content

Docosanol

About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...

HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It offers services such as sourcing, manufacturing & supply, helping partners enter new markets worldwide. Its strong partnerships with major players in the pharma and food additive industries help HRV Global effectively promote projects and products. HRV Global represents over 30 large Indian drugmakers, primarily targeting Europe, the US & the Middle East markets. Headquartered in India, HRV Global has offices in the US, Switzerland, Dubai, Lithuania & Turkey.
HRV Global Life Sciences

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI offers customized CDMO Solutions for API development and manufacturing services.

Flag Israel
Digital Content Digital Content

Docosanol

About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.
TAPI Company Banner

04

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Docosanol

About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...

Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
blank

05

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Docosanol

About the Company : Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its ex...

Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its excellent research & development and aggressive growth strategies. Our 32 US DMFs and 9 CEPs in a short span attest to our R&D excellence. Maithri's manufacturing facility is located in Hyderabad. This facility is audited and approved by the US FDA. In addition, our facility is certified according to the standards of DCGI, WHO GMP, and ISO 9001:2015 We have a portfolio of 65 products and are continually expanding.
blank

06

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Docosanol

About the Company : SKVEN Technologies is a diverse pharmaceutical company that is committed to focusing on our customers while delivering consistently high performance. Our Vision, Mission and in Val...

SKVEN Technologies is a diverse pharmaceutical company that is committed to focusing on our customers while delivering consistently high performance. Our Vision, Mission and in Values provide the overall direction for our company, and provide us with the tools necessary to rise to any challenge by leveraging our collective hard work and effort along with our unwavering competitive spirit. SKVEN expertise and capabilities in pharmaceutical development and manufacturing will provide Customers with customized services and solutions for starting materials, intermediates, active ingredients and finished dosage form.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"DOCOSANOL","year":"2021","qtr":"Q1","strtotime":1611772200,"product":"DOCOSANOL-BATCH NO:320400191\/1320400193\/ 1320400194\/1321400001\/1321400004-MFG DT: 24.12.2020\/28.12.2020\/04.01.2021\/07.01.2","address":"201\/301, CORPORATE ENCLAVE,B D SAWANT MARG, CHAKALA,","city":"ANDHERI (E), MUMBAI,MAHARASHTRA","supplier":"TEVA PHARMACEUTICAL INDUSTRIES","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"ACTAVIS INC","customerCountry":"UNITED STATES","quantity":"214.11","actualQuantity":"214.11","unit":"KGS","unitRateFc":"1460.5","totalValueFC":"316611.9","currency":"USD","unitRateINR":108150,"date":"28-Jan-2021","totalValueINR":"23155996.5","totalValueInUsd":"316611.9","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"8201901","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"201\/301, CORPORATE ENCLAVE,B D SAWANT MARG, CHAKALA,, ANDHERI (E), MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"DOCOSANOL","year":"2021","qtr":"Q1","strtotime":1614191400,"product":"DOCOSANOL-BATCH NO:1321400006 1321400011 1321400012 1321400014 1321400018 132140 0019 1321400005 MFD DT:19.01.2021 27.01.","address":"201\/301, CORPORATE ENCLAVE,B D SAWANT MARG, CHAKALA,","city":"ANDHERI (E), MUMBAI,MAHARASHTRA","supplier":"TEVA PHARMACEUTICAL INDUSTRIES","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"ACTAVIS INC","customerCountry":"UNITED STATES","quantity":"309.14","actualQuantity":"309.14","unit":"KGS","unitRateFc":"1499","totalValueFC":"458572.1","currency":"USD","unitRateINR":108000,"date":"25-Feb-2021","totalValueINR":"33387120","totalValueInUsd":"458572.1","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"8907819","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"201\/301, CORPORATE ENCLAVE,B D SAWANT MARG, CHAKALA,, ANDHERI (E), MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"DOCOSANOL","year":"2021","qtr":"Q1","strtotime":1616351400,"product":"DOCOSANOL","address":"PLOT NO.2, MAITRIVIHAR,BEHIND MAITRIVANAM, AMEERPET,","city":"HYDERABAD\/ANDHRA PRADESH","supplier":"AUROBINDO PHARMA LIMITED","supplierCountry":"INDIA","foreign_port":"HOUSTON TX","customer":"DPT LABORATORIES, LTD","customerCountry":"UNITED STATES","quantity":"80.00","actualQuantity":"80","unit":"KGS","unitRateFc":"2468.4","totalValueFC":"195431.2","currency":"USD","unitRateINR":177845.82500000001,"date":"22-Mar-2021","totalValueINR":"14227666","totalValueInUsd":"195431.2","indian_port":"HYDERABAD AIR","hs_no":"29051990","bill_no":"9539406","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.2, MAITRIVIHAR,BEHIND MAITRIVANAM, AMEERPET,, HYDERABAD\/ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1645381800,"product":"DOCOSANOL","address":"425\/3RT, D.NO.7-1-621\/328,,SANJEEV AREDDY NAGAR,","city":"HYDERABAD,TELANGANA","supplier":"AZICO BIOPHORE INDIA PVT. LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"M\/S.","customerCountry":"TURKEY","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"1500","totalValueFC":"7310.9","currency":"USD","unitRateINR":109600,"date":"21-Feb-2022","totalValueINR":"548000","totalValueInUsd":"7310.9","indian_port":"HYDERABAD AIR","hs_no":"29054900","bill_no":"8382733","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"425\/3RT, D.NO.7-1-621\/328,,SANJEEV AREDDY NAGAR,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652812200,"product":"DOCOSANOL - CONTROL BATCH NO 1617900222","address":"12th floor,Commerz II, International Business Park, Oberoi","city":"Goregaon East","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"MANCHESTER","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"177.03","actualQuantity":"177.03","unit":"KGS","unitRateFc":"1036.3","totalValueFC":"177613.7","currency":"USD","unitRateINR":77540.52985369711,"date":"18-May-2022","totalValueINR":"13727000","totalValueInUsd":"177613.7","indian_port":"DELHI AIR","hs_no":"29054900","bill_no":"1472831","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"12th floor,Commerz II, International Business Park, Oberoi, Goregaon East","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669141800,"product":"DOCOSANOL IH -CONTROL BATCH NO 161790142","address":"12th floor,Commerz II, International Business Park, Oberoi","city":"Goregaon East","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"MANCHESTER","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"181.26","actualQuantity":"181.26","unit":"KGS","unitRateFc":"1181.8","totalValueFC":"211548","currency":"USD","unitRateINR":95249.917245945049,"date":"23-Nov-2022","totalValueINR":"17265000","totalValueInUsd":"211548","indian_port":"DELHI AIR","hs_no":"29054900","bill_no":"5652878","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"12th floor,Commerz II, International Business Park, Oberoi, Goregaon East","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669141800,"product":"DOCOSANOL IH -CONTROL BATCH NO 161790172","address":"12th floor,Commerz II, International Business Park, Oberoi","city":"Goregaon East","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"MANCHESTER","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"158.79","actualQuantity":"158.79","unit":"KGS","unitRateFc":"1181.8","totalValueFC":"185326.6","currency":"USD","unitRateINR":95251.590150513264,"date":"23-Nov-2022","totalValueINR":"15125000","totalValueInUsd":"185326.6","indian_port":"DELHI AIR","hs_no":"29054900","bill_no":"5652878","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"12th floor,Commerz II, International Business Park, Oberoi, Goregaon East","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1672079400,"product":"DOCOSANOL - CONTROL BATCH NO 1617901822","address":"12TH FLOOR,COMMERZ II, INTERNATIONAL BUSINESS PARK, OBEROI","city":"Goregaon East","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"MANCHESTER","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"172.76","actualQuantity":"172.76","unit":"KGS","unitRateFc":"1181.8","totalValueFC":"201841.5","currency":"USD","unitRateINR":96278.073628154671,"date":"27-Dec-2022","totalValueINR":"16633000","totalValueInUsd":"201841.5","indian_port":"DELHI AIR","hs_no":"29054900","bill_no":"6471948","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"12TH FLOOR,COMMERZ II, INTERNATIONAL BUSINESS PARK, OBEROI, Goregaon East","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1672079400,"product":"DOCOSANOL - CONTROL BATCH NO 1617902022","address":"12TH FLOOR,COMMERZ II, INTERNATIONAL BUSINESS PARK, OBEROI","city":"Goregaon East","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"MANCHESTER","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"181.16","actualQuantity":"181.16","unit":"KGS","unitRateFc":"1181.8","totalValueFC":"211658.7","currency":"USD","unitRateINR":96279.531905497905,"date":"27-Dec-2022","totalValueINR":"17442000","totalValueInUsd":"211658.7","indian_port":"DELHI AIR","hs_no":"29054900","bill_no":"6471948","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"12TH FLOOR,COMMERZ II, INTERNATIONAL BUSINESS PARK, OBEROI, Goregaon East","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1672079400,"product":"DOCOSANOL - CONTROL BATCH NO 1617902122","address":"12TH FLOOR,COMMERZ II, INTERNATIONAL BUSINESS PARK, OBEROI","city":"Goregaon East","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"MANCHESTER","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"181.31","actualQuantity":"181.31","unit":"KGS","unitRateFc":"1181.8","totalValueFC":"211828.6","currency":"USD","unitRateINR":96277.094479068997,"date":"27-Dec-2022","totalValueINR":"17456000","totalValueInUsd":"211828.6","indian_port":"DELHI AIR","hs_no":"29054900","bill_no":"6471948","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"12TH FLOOR,COMMERZ II, INTERNATIONAL BUSINESS PARK, OBEROI, Goregaon East","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703269800,"product":"DOCOSANOL - CATALOG-70401617 CONTROL NO.1617900523 MFG DT SEPTEMBER 2023 RETEST DT. AUGUST 2028","address":"M-34, SAKET,","city":"NEW DELHI,DELHI","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"SOUTHAMPTON","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"175.23","actualQuantity":"175.23","unit":"KGS","unitRateFc":"781","totalValueFC":"135554.7","currency":"USD","unitRateINR":64395.36609028135,"date":"23-Dec-2023","totalValueINR":"11284000","totalValueInUsd":"135554.7","indian_port":"Dadri-CGML","hs_no":"29054900","bill_no":"6270612","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Dadri-CGML","supplierAddress":"M-34, SAKET,, NEW DELHI,DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703269800,"product":"DOCOSANOL - CATALOG-70401617 CONTROL NO.1617900623 MFG DT SEPTEMBER 2023 RETEST DT.AUGUST 2028","address":"M-34, SAKET,","city":"NEW DELHI,DELHI","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"SOUTHAMPTON","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"180.00","actualQuantity":"180","unit":"KGS","unitRateFc":"781","totalValueFC":"139242.7","currency":"USD","unitRateINR":64394.444444444445,"date":"23-Dec-2023","totalValueINR":"11591000","totalValueInUsd":"139242.7","indian_port":"Dadri-CGML","hs_no":"29054900","bill_no":"6270612","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Dadri-CGML","supplierAddress":"M-34, SAKET,, NEW DELHI,DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703269800,"product":"DOCOSANOL - CATALOG-70401617 CONTROL NO.1617900723 MFG DT OCTOBER 2023 RETEST DT. SEPTEMBER 2028","address":"M-34, SAKET,","city":"NEW DELHI,DELHI","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"SOUTHAMPTON","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"178.23","actualQuantity":"178.23","unit":"KGS","unitRateFc":"781","totalValueFC":"137873.2","currency":"USD","unitRateINR":64394.321943556082,"date":"23-Dec-2023","totalValueINR":"11477000","totalValueInUsd":"137873.2","indian_port":"Dadri-CGML","hs_no":"29054900","bill_no":"6270612","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Dadri-CGML","supplierAddress":"M-34, SAKET,, NEW DELHI,DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703269800,"product":"DOCOSANOL - CATALOG-70401617 CONTROL NO.1617901123 MFG DT NOVEMBER 2023 RETESTDT. OCTOBER 2028","address":"M-34, SAKET,","city":"NEW DELHI,DELHI","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"SOUTHAMPTON","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"177.66","actualQuantity":"177.66","unit":"KGS","unitRateFc":"781","totalValueFC":"137488.8","currency":"USD","unitRateINR":64420.803782505915,"date":"23-Dec-2023","totalValueINR":"11445000","totalValueInUsd":"137488.8","indian_port":"Dadri-CGML","hs_no":"29054900","bill_no":"6270612","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Dadri-CGML","supplierAddress":"M-34, SAKET,, NEW DELHI,DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703269800,"product":"DOCOSANOL - CATALOG-70401617 CONTROL NO.1617901423 MFG DT NOVEMBER 2023 RETESTDT. OCTOBER 2028","address":"M-34, SAKET,","city":"NEW DELHI,DELHI","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"SOUTHAMPTON","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"177.96","actualQuantity":"177.96","unit":"KGS","unitRateFc":"781","totalValueFC":"137717","currency":"USD","unitRateINR":64418.970555180938,"date":"23-Dec-2023","totalValueINR":"11464000","totalValueInUsd":"137717","indian_port":"Dadri-CGML","hs_no":"29054900","bill_no":"6270612","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Dadri-CGML","supplierAddress":"M-34, SAKET,, NEW DELHI,DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703269800,"product":"DOCOSANOL - CATALOG-70401617 CONTROL NO.1617901523 MFG DT NOVEMBER 2023 RETESTDT. OCTOBER 2028","address":"M-34, SAKET,","city":"NEW DELHI,DELHI","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"SOUTHAMPTON","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"91.26","actualQuantity":"91.26","unit":"KGS","unitRateFc":"781","totalValueFC":"70516.3","currency":"USD","unitRateINR":64321.718167872008,"date":"23-Dec-2023","totalValueINR":"5870000","totalValueInUsd":"70516.3","indian_port":"Dadri-CGML","hs_no":"29054900","bill_no":"6270612","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Dadri-CGML","supplierAddress":"M-34, SAKET,, NEW DELHI,DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703269800,"product":"DOCOSANOL - CATALOG-70401617 CONTROL NO.1617901723 MFG DT NOVEMBER 2023 RETESTDT. OCTOBER 2028","address":"M-34, SAKET,","city":"NEW DELHI,DELHI","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"SOUTHAMPTON","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"176.91","actualQuantity":"176.91","unit":"KGS","unitRateFc":"781","totalValueFC":"136707.9","currency":"USD","unitRateINR":64326.493697360238,"date":"23-Dec-2023","totalValueINR":"11380000","totalValueInUsd":"136707.9","indian_port":"Dadri-CGML","hs_no":"29054900","bill_no":"6270612","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Dadri-CGML","supplierAddress":"M-34, SAKET,, NEW DELHI,DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1732559400,"product":"DOCOSANOL - CATALOG-70401617 CONTROL NO.1617900224 MFG DT,JUNE 2024 RETEST DT.MAY 2029","address":"M-34, SAKET,","city":"NEW DELHI,DELHI","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"SOUTHAMPTON","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"179.08","actualQuantity":"179.08","unit":"KGS","unitRateFc":"677.7","totalValueFC":"119757","currency":"USD","unitRateINR":56433.294896135798,"date":"26-Nov-2024","totalValueINR":"10106074.45","totalValueInUsd":"119757","indian_port":"Dadri-CGML","hs_no":"29054900","bill_no":"5917789","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Dadri-CGML","supplierAddress":"M-34, SAKET,, NEW DELHI,DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1732559400,"product":"DOCOSANOL - CATALOG-70401617 CONTROL NO.1617900724 MFG DT.JULY 2024 RETEST DT. JUNE 2029","address":"M-34, SAKET,","city":"NEW DELHI,DELHI","supplier":"TEVA API","supplierCountry":"INDIA","foreign_port":"SOUTHAMPTON","customer":"GSK","customerCountry":"UNITED KINGDOM","quantity":"175.86","actualQuantity":"175.86","unit":"KGS","unitRateFc":"677.7","totalValueFC":"117617.8","currency":"USD","unitRateINR":56440.092630501531,"date":"26-Nov-2024","totalValueINR":"9925554.69","totalValueInUsd":"117617.8","indian_port":"Dadri-CGML","hs_no":"29054900","bill_no":"5917789","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Dadri-CGML","supplierAddress":"M-34, SAKET,, NEW DELHI,DELHI","customerAddress":""}]
28-Jan-2021
26-Nov-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Europe

read-more
read-more

01

Jenson Pharmaceutical Services Ltd.

Country
Duphat
Not Confirmed
arrow

Jenson Pharmaceutical Services Ltd.

Country
arrow
Duphat
Not Confirmed

docosanol

Brand Name : Healip

Dosage Form : CREAM

Dosage Strength : 10%

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Topical

read-more
read-more

Solubilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Parenteral

read-more
read-more

Emulsifying Agents

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Abreva Manufacturers

A Abreva manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Abreva, including repackagers and relabelers. The FDA regulates Abreva manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Abreva API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Abreva manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Abreva Suppliers

A Abreva supplier is an individual or a company that provides Abreva active pharmaceutical ingredient (API) or Abreva finished formulations upon request. The Abreva suppliers may include Abreva API manufacturers, exporters, distributors and traders.

click here to find a list of Abreva suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Abreva USDMF

A Abreva DMF (Drug Master File) is a document detailing the whole manufacturing process of Abreva active pharmaceutical ingredient (API) in detail. Different forms of Abreva DMFs exist exist since differing nations have different regulations, such as Abreva USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Abreva DMF submitted to regulatory agencies in the US is known as a USDMF. Abreva USDMF includes data on Abreva's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Abreva USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Abreva suppliers with USDMF on PharmaCompass.

Abreva WC

A Abreva written confirmation (Abreva WC) is an official document issued by a regulatory agency to a Abreva manufacturer, verifying that the manufacturing facility of a Abreva active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Abreva APIs or Abreva finished pharmaceutical products to another nation, regulatory agencies frequently require a Abreva WC (written confirmation) as part of the regulatory process.

click here to find a list of Abreva suppliers with Written Confirmation (WC) on PharmaCompass.

Abreva NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Abreva as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Abreva API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Abreva as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Abreva and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Abreva NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Abreva suppliers with NDC on PharmaCompass.

Abreva GMP

Abreva Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Abreva GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Abreva GMP manufacturer or Abreva GMP API supplier for your needs.

Abreva CoA

A Abreva CoA (Certificate of Analysis) is a formal document that attests to Abreva's compliance with Abreva specifications and serves as a tool for batch-level quality control.

Abreva CoA mostly includes findings from lab analyses of a specific batch. For each Abreva CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Abreva may be tested according to a variety of international standards, such as European Pharmacopoeia (Abreva EP), Abreva JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Abreva USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty